More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as ...

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.00. Protect Your Portfolio Against Market Uncertai ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. Protect Your ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Key Takeaways A Medicaid policy change left fewer kids with access to an asthma inhalerChildren were more likely to have no ...

For as long as cancer treatment has existed, ‘cutting it out has been the best way to cure it.’” Those are the words of ...

BOSTON and SHANGHAI, May 01, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...